193 related articles for article (PubMed ID: 12011124)
21. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.
Kaiser U; Uebelacker I; Abel U; Birkmann J; Trümper L; Schmalenberg H; Karakas T; Metzner B; Hossfeld DK; Bischoff HG; Franke A; Reiser M; Müller P; Mantovani L; Grundeis M; Rothmann F; von Seydewitz CU; Mesters RM; Steinhauer EU; Krahl D; Schumacher K; Kneba M; Baudis M; Schmitz N; Pfab R; Köppler H; Parwaresch R; Pfreundschuh M; Havemann K
J Clin Oncol; 2002 Nov; 20(22):4413-9. PubMed ID: 12431962
[TBL] [Abstract][Full Text] [Related]
22. CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Prayoonwiwat W; Numbenjapon T; Assawametha N; O'Charoen R; Swasdikul D
Clin Lymphoma; 2000 Dec; 1(3):219-25. PubMed ID: 11707834
[TBL] [Abstract][Full Text] [Related]
23. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).
Ketterer N; Coiffier B; Thieblemont C; Fermé C; Brière J; Casasnovas O; Bologna S; Christian B; Connerotte T; Récher C; Bordessoule D; Fruchart C; Delarue R; Bonnet C; Morschhauser F; Anglaret B; Soussain C; Fabiani B; Tilly H; Haioun C
Ann Oncol; 2013 Apr; 24(4):1032-7. PubMed ID: 23235801
[TBL] [Abstract][Full Text] [Related]
24. Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte.
Diviné M; Lepage E; Brière J; Pautier P; Dupriez B; Lederlin P; Mineur P; Tilly H; Blanc M; Audhuy B; Herbrecht R; Coiffier B; Reyes F
J Clin Oncol; 1996 Jan; 14(1):240-8. PubMed ID: 8558204
[TBL] [Abstract][Full Text] [Related]
25. Upfront autologous stem cell transplantation for untreated high-risk diffuse large B-cell lymphoma in patients up to 60 years of age.
Takasaki H; Hashimoto C; Fujita A; Matsumoto K; Taguchi J; Kuwabara H; Yamazaki E; Koharazawa H; Fujita H; Fujisawa S; Ishii Y; Yamamoto W; Motomura S; Tomita N; Ishigatsubo Y; Sakai R
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):404-9. PubMed ID: 23763919
[TBL] [Abstract][Full Text] [Related]
26. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma.
Haioun C; Mounier N; Emile JF; Ranta D; Coiffier B; Tilly H; Récher C; Fermé C; Gabarre J; Herbrecht R; Morchhauser F; Gisselbrecht C
Ann Oncol; 2009 Dec; 20(12):1985-92. PubMed ID: 19567453
[TBL] [Abstract][Full Text] [Related]
27. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.
Dreger P; Martin S; Kuse R; Sonnen R; Glass B; Kröger N; Parwaresch R; Kneba M; Schmitz N; Haas R
Hematol J; 2000; 1(2):87-94. PubMed ID: 11920175
[TBL] [Abstract][Full Text] [Related]
28. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.
Haioun C; Lepage E; Gisselbrecht C; Coiffier B; Bosly A; Tilly H; Morel P; Nouvel C; Herbrecht R; D'Agay MF
J Clin Oncol; 1994 Dec; 12(12):2543-51. PubMed ID: 7527453
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.
Jabbour E; Peslin N; Arnaud P; Ferme C; Carde P; Vantelon JM; Bocaccio C; Bourhis JH; Koscielny S; Ribrag V
Leuk Lymphoma; 2005 Jun; 46(6):861-7. PubMed ID: 16019530
[TBL] [Abstract][Full Text] [Related]
30. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
[TBL] [Abstract][Full Text] [Related]
31. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial.
Vitolo U; Liberati AM; Cabras MG; Federico M; Angelucci E; Baldini L; Boccomini C; Brugiatelli M; Calvi R; Ciccone G; Genua A; Deliliers GL; Levis A; Parvis G; Pavone E; Salvi F; Sborgia M; Gallo E;
Haematologica; 2005 Jun; 90(6):793-801. PubMed ID: 15951292
[TBL] [Abstract][Full Text] [Related]
32. Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial.
Ahn JS; Yang DH; Jung SH; Chae YS; Sohn SK; Yhim HY; Kwak JY; Lee SR; Kim YK; Kim HJ; Lee JJ
Ann Hematol; 2013 Jun; 92(6):789-97. PubMed ID: 23358616
[TBL] [Abstract][Full Text] [Related]
33. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).
Schmitz N; Nickelsen M; Ziepert M; Haenel M; Borchmann P; Schmidt C; Viardot A; Bentz M; Peter N; Ehninger G; Doelken G; Ruebe C; Truemper L; Rosenwald A; Pfreundschuh M; Loeffler M; Glass B;
Lancet Oncol; 2012 Dec; 13(12):1250-9. PubMed ID: 23168367
[TBL] [Abstract][Full Text] [Related]
34. Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin's lymphoma patients: a prospective randomized GEMOH report.
Baldissera RC; Nucci M; Vigorito AC; Maiolino A; Simões BP; Lorand-Metze I; Aranha FJ; Miranda EC; Pagnano KB; Ruiz MA; Moraes AA; De Souza CA
Acta Haematol; 2006; 115(1-2):15-21. PubMed ID: 16424644
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.
Coiffier B; Gisselbrecht C; Vose JM; Tilly H; Herbrecht R; Bosly A; Armitage JO
J Clin Oncol; 1991 Feb; 9(2):211-9. PubMed ID: 1703226
[TBL] [Abstract][Full Text] [Related]
36. Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA).
Mounier N; Haioun C; Cole BF; Gisselbrecht C; Sebban C; Morel P; Marit G; Bouabdallah R; Ravoet C; Salles G; Reyes F; Lepage E
Blood; 2000 Jun; 95(12):3687-92. PubMed ID: 10845898
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study.
Monjanel H; Deconinck E; Perrodeau E; Gastinne T; Delwail V; Moreau A; François S; Berthou C; Gyan E; Milpied N;
Biol Blood Marrow Transplant; 2011 Jun; 17(6):935-40. PubMed ID: 21109011
[TBL] [Abstract][Full Text] [Related]
38. [High-dose chemotherapy with autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in complete response as consolidation therapy, second report].
Yamane T; Hirose A; Nakajima Y; Nakane T; Koh H; Takeoka Y; Nakamae M; Yamamura R; Nakamae H; Nakao Y; Mugitani A; Yagi T; Teshima H; Hino M
Gan To Kagaku Ryoho; 2006 Feb; 33(2):193-8. PubMed ID: 16484855
[TBL] [Abstract][Full Text] [Related]
39. Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG.
Olivieri A; Santini G; Patti C; Chisesi T; De Souza C; Rubagotti A; Aversa S; Billio A; Porcellini A; Candela M; Centurioni R; Congiu AM; Brunori M; Nati S; Spriano M; Vimercati R; Marino G; Contu A; Tedeschi L; Majolino I; Crugnola M; Sertoli MR;
Ann Oncol; 2005 Dec; 16(12):1941-8. PubMed ID: 16157621
[TBL] [Abstract][Full Text] [Related]
40. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.
Fitoussi O; Belhadj K; Mounier N; Parrens M; Tilly H; Salles G; Feugier P; Ferme C; Ysebaert L; Gabarre J; Herbrecht R; Janvier M; Van Den Neste E; Morschhauser F; Casasnovas O; Ghesquieres H; Anglaret B; Brechignac S; Haioun C; Gisselbrecht C
Haematologica; 2011 Aug; 96(8):1136-43. PubMed ID: 21546499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]